Ocata Therapeutics Inc fka OCAT

[NYPharmer1]

Part 6

News Affecting ACTC

Judge Throws Out Stem Cell Lawsuit

by Jocelyn Kaiser
A federal judge has rejected a lawsuit challenging the Obama Administration's policy lifting restrictions on using federal funds to study human embryonic stem cells. Christian groups had sued the National Institutes of Health in August, arguing on behalf of themselves and embryos that NIH's stem cell guidelines violate a ban on using federal funds to create or destroy human embryos. According to Bloomberg, U.S. District Court Judge Royce Lamberth ruled yesterday in Washington, D.C., that the groups had no standing because the U.S. Supreme Court has found that embryos are not persons under the law, and the unborn have no constitutional right to life. The AP's story says the judge also rejected the argument that the guidelines would reduce the number of embryos available for adoption. http://blogs.sciencemag.org/scienceinsider/2009/10/judge-throws-ou.html

Recent Company News

Advanced Cell Technology, Inc.'s Shares To Trade On Over-the-Counter Bulletin Board
Tuesday, 6 Oct 2009 07:40am EDT
Advanced Cell Technology, Inc. announced that effective immediately the Company's shares will be traded on the Over-the-Counter Bulletin Board under its previous ticker symbol ACTC. The Company is now fully reporting and up-to-date with all of its filing requirements. The Company`s stock had previously traded on the Pink Sheets.

Advanced Cell Technology, Inc. Completing Pre-Clinical Activities In Preparation For IND Filing
Tuesday, 22 Sep 2009 11:28am EDT
Advanced Cell Technology, Inc. announced an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. In the next few weeks, the Company will be completing the preclinical work necessary for filing the IND. To date, no adverse events have occurred in testing. The results will be part of the submission which Advanced Cell expects to submit to the FDA prior to the end of the year.

Advanced Cell Technology, Inc. and Collaborators At The Casey Eye Institute Present Promising Data Supporting Safety and Efficacy of Stem Cell Therapy to Combat Retinal Disease
Friday, 12 Jun 2009 09:39am EDT
Advanced Cell Technology, Inc. and its collaborators at OHSU reported the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for human clinical trials. Two important early potential hESC applications are the use of RPE for the treatment of age-related macular degeneration and Stargardt disease, an untreatable form of eye disease that leads to early-onset blindness. The research, which appears online ahead of print in the journal Stem Cells, shows long-term functional rescue using hESC-derived cells in both the RCS rat and Elov14 mouse, animal models of retinal degeneration and Stargardt, respectively. The cells survived transplantation for prolonged periods (>220 days) and sustained visual function without tumor formation or untoward pathological reactions. Near-normal functional rescue was also achieved in the `Stargardt` mouse. To further address safety concerns, a study was carried out in the NIH III immune deficient mouse model. Long-term data (spanning the life of the animals) revealed no evidence of tumor formation after transplantation.

Advanced Cell Technology, Inc. Prepares IND Filing with the Capability to Produce Stem Cell Lines without the Destruction of the Embryo
Thursday, 12 Mar 2009 08:00am EDT
Advanced Cell Technology, Inc. announced that it is finalizing preparations to file an IND in the second half of this year with the Food and Drug Administration for the Company's retinal pigment epithelium (RPE) cell program for the treatment of diseases of the eye. It has available the only technology that can today produce stem cell lines without the destruction of the embryo. While President Obama recently issued an Executive Order that authorizes expanded federal funding for research using stem cells produced by destroying human embryos, the decision remains controversial as some believe that the Government should not fund the ongoing destruction of human embryos. In the coming months Congress will be debating altering or eliminating the Dickey Wicker Amendment which is at the core of this controversy. Advanced Cell Technology`s stem cell platform offers a compromise on this issue, as described in peer review scientific journals published over the past several years. Over 3000 healthy children have undergone the medical procedure, PGD, which is at the core of ACTC`s technology.






Michael Vlaicu
MiV Investments Inc.
www.StocksHaven.com
President & CEO

"Some people dream of great accomplishments,
while others stay awake and do them"
-----------
By reading MiV Investments Inc. e-mail alerts you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

MiV Investments Inc. is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated